Preeclampsia is a pregnancy complication characterized by high blood pressure and presence of protein in the urine after 20 weeks of gestation. It can be a dangerous condition for both mother and baby, if undetected. Early diagnosis is crucial to allow clinicians to closely monitor the condition and deliver the baby if preeclampsia worsens. Traditional diagnostic methods rely on clinical signs and symptoms, which have limitations. Global preeclampsia diagnostics market can witness growth due to increasing awareness about the condition. Various new diagnostic tools are being developed and adopted to screen women at risk and enable timely identification of the disorder. 

Market Dynamics:

Global preeclampsia diagnostics market growth is driven by growing incidence of preeclampsia worldwide. According to recent estimates, preeclampsia complicates around 5-8% of all pregnancies globally. Rising maternal age of first-time mothers can contribute to its rising caseload. New product launches and increasing adoption of advanced diagnostic technologies for early screening can offer opportunities for market growth. However, limited awareness about preeclampsia in low income regions and lack of universal healthcare can hamper the market growth. High cost of new diagnostic devices can pose challenge, especially in price-sensitive developing markets.

Key Features of the Study:

• This report provides in-depth analysis of the global preeclampsia diagnostics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global preeclampsia diagnostics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Roche, Thermo Fischer Scientific, Bayer, Siemens Healthineers, DRG Instruments GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global preeclampsia diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preeclampsia diagnostics market

Detailed Segmentation-

• By Test Type
  
  • Blood Tests
  • Urine Analysis
  • Others
• By Product Type
  
  • Instruments
  • Consumables
• By End User
  • Hospital
  • Specialty Clinics
  • Diagnostic Centers
  • Others
• By Region:       
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Roche Diagnostic
  • Thermo Fisher Giving Inc.
  • PerkinElmer
  • Siemens Healthineers
  • Abbott Laboratories
  • Beckman Coulter
  • Becton, Dickinson and Company (BD)
  • bioMérieux
  • Hoffmann-La Roche Ltd
  • Metabolomic Diagnostics Ltd
  • Diabetomics, Inc.
  • Quidel Corporation
  • Sera Prognostics
  • Brahms GmbH
  • The Progenix GrouP